We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Costimulatory Molecules as Biomarkers in Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01353950
Recruitment Status : Completed
First Posted : May 16, 2011
Last Update Posted : April 6, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to investigate the expression of a certain class of molecules, called costimulatory molecules, in humans with Cystic Fibrosis. Cystic Fibrosis is a genetic disorder which renders the lung susceptible to persistent inflammation which, at times, can worsen, resulting in accelerated decline in lung function and eventually death or transplant. Our goal is to determine if the levels of costimulatory markers can be used to predict exacerbation and subsequent lung function decline in subjects with Cystic Fibrosis.

Condition or disease
Cystic Fibrosis

Study Design

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Costimulatory Molecules as Biomarkers in Cystic Fibrosis
Study Start Date : July 2011
Primary Completion Date : June 2013
Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
U.S. FDA Resources

Groups and Cohorts

Adult Cystic Fibrosis Patients
Adults with Cystic Fibrosis will be followed longitudinally for 2 years

Outcome Measures

Biospecimen Retention:   Samples Without DNA
Plasma, Serum, urine

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults with Cystic Fibrosis

Inclusion Criteria:

  • Willingness to participate

Exclusion Criteria:

  • Presence of HIV
  • Presence of Lymphoma/Leukemia
  • Presence of Lung or other solid organ Transplant
  • Pregnancy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01353950

United States, Oregon
Oregon health and Sciences University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
More Information

Responsible Party: Jeffrey Gold, professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01353950     History of Changes
Other Study ID Numbers: IRB00007132
First Posted: May 16, 2011    Key Record Dates
Last Update Posted: April 6, 2017
Last Verified: April 2017

Keywords provided by Jeffrey Gold, Oregon Health and Science University:
Costimulatory molecules
Cystic Fibrosis

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases